YOSEMITE and RHINE

Key Points

Key points are not available for this paper at this time.

Abstract

YOSEMITE and RHINE were the first registrational trials in retinal disease to incorporate an objective PTI regimen, allowing for up to every-16-week adjustable dosing with a dual angiopoietin-2 and VEGF-A inhibitor, faricimab 6.0 mg, for treatment of DME.

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Eter et al. (Thu,) studied this question.

synapsesocial.com/papers/69dd5fb2629747396240ca5b https://doi.org/https://doi.org/10.1016/j.xops.2021.100111

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1<p>Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia</p>2019 · 53 citations
2One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study2020 · 26 citations
3Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes2020 · 150 citations
4Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature2016 · 81 citations
5Intravitreal Aflibercept for Diabetic Macular Edema2015 · 615 citations